Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab recommended for approval in EU by CHMP
Investegate announcements from AstraZeneca PLC, Nirsevimab recommended for approval in EU by CHMP
Source: investegate.co.uk
Page 4 - Drug Selection News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Drug Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Drug Selection Today - Breaking & Trending Today
Beyfortus recommended for approval by CHMP for RSV disease in infants
The CHMP had adopted a positive opinion for Beyfortus to treat RSV lower respiratory tract disease in newborns and infants.
Source: labiotech.eu
New nirsevimab data analyses reinforce efficacy against RSV
New nirsevimab data analyses reinforce efficacy against RSVA prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the firs...
Source: pharmiweb.com
Sanofi - Aventis Groupe: Press Release: New nirsevimab data analyses reinforce efficacy against RSV
New nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory
Source: finanznachrichten.de
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com